

# Martti Antero FÄörkkilÄö

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2514777/publications.pdf>

Version: 2024-02-01

176  
papers

15,888  
citations

41323

49  
h-index

20943

115  
g-index

186  
all docs

186  
docs citations

186  
times ranked

27086  
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational constraint spectrum quantified from variation in 141,456 humans. <i>Nature</i> , 2020, 581, 434-443.	13.7	6,140
2	A structural variation reference for medical and population genetics. <i>Nature</i> , 2020, 581, 444-451.	13.7	614
3	Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1909-1915.	6.3	517
4	Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 40-46.	0.9	397
5	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 1198-1206.	0.6	394
6	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
7	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. <i>Nature Genetics</i> , 2013, 45, 670-675.	9.4	339
8	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 269-273.	9.4	230
9	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	3.7	208
10	Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1392-1398.	0.9	206
11	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
12	Randomized comparison of 12 or 24 weeks of peginterferon $\alpha$ -2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2008, 47, 1837-1845.	3.6	196
13	Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: A randomized placebo-controlled trial. <i>Hepatology</i> , 2004, 40, 1379-1386.	3.6	180
14	Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. <i>Hepatology</i> , 2018, 67, 2141-2149.	3.6	178
15	IL-23/IL-17 immunity as a hallmark of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1175-1184.	0.9	172
16	Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF $\alpha$ blocking agents. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2011-2017.	0.9	158
17	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Endoscopy</i> , 2017, 49, 588-608.	1.0	154
18	Transcript expression-aware annotation improves rare variant interpretation. <i>Nature</i> , 2020, 581, 452-458.	13.7	142

#	ARTICLE	IF	CITATIONS
19	Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 325-331.	0.6	140
20	Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 528-537.	0.6	139
21	Esophageal Morbidity and Function in Adults With Repaired Esophageal Atresia With Tracheoesophageal Fistula. <i>Annals of Surgery</i> , 2010, 251, 1167-1173.	2.1	137
22	Endoscopic evaluation of Crohn's disease activity. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 2131-2136.	0.9	130
23	Evaluating drug targets through human loss-of-function genetic variation. <i>Nature</i> , 2020, 581, 459-464.	13.7	115
24	Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 380-388.e4.	0.6	114
25	Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis. <i>Hepatology</i> , 2015, 62, 188-197.	3.6	106
26	Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow-up of Population Cohorts. <i>Hepatology</i> , 2020, 71, 835-848.	3.6	96
27	Achievement of deep remission during scheduled maintenance therapy with TNF-blocking agents in IBD. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 730-735.	0.6	95
28	Helsinki alert of biodiversity and health. <i>Annals of Medicine</i> , 2015, 47, 218-225.	1.5	95
29	Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 484-498.	0.6	93
30	Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 778-784.	0.6	88
31	Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. <i>Journal of Hepatology</i> , 2017, 66, 1265-1281.	1.8	87
32	Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 430-435.	3.6	82
33	Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1405-1413.	0.6	80
34	Does fecal calprotectin predict short-term relapse after stopping TNF-blocking agents in inflammatory bowel disease patients in deep remission?. <i>Journal of Crohn's and Colitis</i> , 2014, 9, 33-40.	0.6	80
35	Validation of the prognostic value of histologic scoring systems in primary sclerosing cholangitis: An international cohort study. <i>Hepatology</i> , 2017, 65, 907-919.	3.6	79
36	Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 41-47.	0.6	74

#	ARTICLE	IF	CITATIONS
37	Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case-control observational study based on registry data. <i>International Journal of Cancer</i> , 2014, 134, 189-196.	2.3	74
38	Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. <i>PLoS ONE</i> , 2017, 12, e0182924.	1.1	71
39	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2018, 155, 752-759.e5.	0.6	69
40	Outcome After Discontinuation of TNF-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1.	0.9	67
41	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. <i>PLoS Genetics</i> , 2018, 14, e1007329.	1.5	66
42	Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1118-1124.	0.9	65
43	Magnetic resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukaemia. <i>European Journal of Haematology</i> , 1996, 56, 82-87.	1.1	62
44	IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. <i>BMC Medical Genetics</i> , 2009, 10, 8.	2.1	61
45	Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 543-551.	0.6	60
46	Quality of life following laparoscopic Nissen fundoplication: Assessing short-term and long-term outcomes. <i>World Journal of Gastroenterology</i> , 2013, 19, 3810.	1.4	60
47	Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 1347-1353.	0.6	59
48	Mortality and causes of death in patients with inflammatory bowel disease: A nationwide register study in Finland. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1088-1096.	0.6	59
49	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. <i>Journal of Hepatology</i> , 2021, 74, 321-329.	1.8	55
50	Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multicentre study. <i>Liver International</i> , 2017, 37, 1554-1561.	1.9	54
51	A High Prevalence of Gastrointestinal Manifestations in Common Variable Immunodeficiency. <i>American Journal of Gastroenterology</i> , 2019, 114, 648-655.	0.2	53
52	PepT1 oligopeptide transporter (SLC15A1) gene polymorphism in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1562-1569.	0.9	51
53	Increasing incidence of inflammatory bowel diseases between 2000 and 2007: A nationwide register study in Finland. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 555-561.	0.9	51
54	High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e256-e262.	0.6	51

#	ARTICLE	IF	CITATIONS
55	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. <i>Journal of Hepatology</i> , 2017, 66, 1214-1222.	1.8	51
56	Patient-controlled sedation with propofol and remifentanyl for ERCP: a randomized, controlled study. <i>Gastrointestinal Endoscopy</i> , 2011, 73, 260-266.	0.5	50
57	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	5.8	50
58	Societal costs for irritable bowel syndrome – a population based study. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 582-591.	0.6	49
59	Unexpectedly High Prevalence of Common Variable Immunodeficiency in Finland. <i>Frontiers in Immunology</i> , 2017, 8, 1190.	2.2	49
60	Comorbidity and use of health-care services among irritable bowel syndrome sufferers. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 799-806.	0.6	48
61	Capsule endoscopy in pediatric patients: Technique and results in our first 100 consecutive children. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1138-1143.	0.6	48
62	Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. <i>Quality of Life Research</i> , 2009, 18, 961-969.	1.5	46
63	Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus. <i>Journal of Infectious Diseases</i> , 2011, 203, 1748-1752.	1.9	45
64	Genetic analysis in Finnish families with inflammatory bowel disease supports linkage to chromosome 3p21. <i>European Journal of Human Genetics</i> , 2001, 9, 328-334.	1.4	43
65	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
66	Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities. <i>Hepatology</i> , 2020, 72, 1253-1266.	3.6	42
67	Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. <i>Digestive and Liver Disease</i> , 2019, 51, 1294-1299.	0.4	41
68	Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. <i>Seminars in Liver Disease</i> , 2020, 40, 154-162.	1.8	41
69	A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. <i>Endoscopy</i> , 2013, 45, 915-919.	1.0	40
70	Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. <i>Hepatology</i> , 2014, 59, 2131-2139.	3.6	38
71	Infliximab-induced skin manifestations in patients with inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 563-571.	0.6	38
72	Epidemiology, risk of malignancy and patient survival in primary sclerosing cholangitis: a population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 74-81.	0.6	37

#	ARTICLE	IF	CITATIONS
73	Screening primary sclerosing cholangitis and biliary dysplasia with endoscopic retrograde cholangiography and brush cytology: risk factors for biliary neoplasia. <i>Endoscopy</i> , 2016, 48, 432-439.	1.0	34
74	Interaction Between Alcohol Use and Metabolic Risk Factors for Liver Disease: A Critical Review of Epidemiological Studies. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 384-403.	1.4	33
75	Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. <i>PLoS ONE</i> , 2012, 7, e29370.	1.1	32
76	Health-related quality of life in inflammatory bowel disease measured with the generic 15D instrument. <i>Quality of Life Research</i> , 2010, 19, 919-928.	1.5	31
77	Endoscopic monitoring of infliximab therapy in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 947-953.	0.9	31
78	Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. <i>Liver International</i> , 2012, 32, 783-789.	1.9	30
79	Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3123-3130.	1.1	30
80	Incidence, survival and cause-specific mortality in alcoholic liver disease: a population-based cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 961-966.	0.6	29
81	Lipid Metabolism in Bile Acid Malabsorption. <i>Annals of Medicine</i> , 1990, 22, 5-13.	1.5	28
82	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. <i>Gastroenterology</i> , 2021, 161, 1764-1775.e5.	0.6	28
83	Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections – A Scandinavian real-life study. <i>PLoS ONE</i> , 2017, 12, e0179764.	1.1	28
84	Medication use among inflammatory bowel disease patients: excessive consumption of antidepressants and analgesics. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 42-50.	0.6	27
85	Serum lipopolysaccharides predict advanced liver disease in the general population. <i>JHEP Reports</i> , 2019, 1, 345-352.	2.6	27
86	Effect of smoking on gastric histology in <i>Helicobacter pylori</i> -positive gastritis. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1177-1183.	0.6	26
87	Metabolism of cholesterol and low- and high-density lipoproteins in primary biliary cirrhosis: Cholesterol absorption and synthesis related to lipoprotein levels and their kinetics. <i>Hepatology</i> , 1995, 21, 89-95.	3.6	25
88	Health-related quality of life among patients with primary sclerosing cholangitis. <i>Liver International</i> , 2015, 35, 2194-2201.	1.9	25
89	Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland. <i>BMJ Open</i> , 2021, 11, e046667.	0.8	25
90	Serum cholestanol, cholesterol precursors, and plant sterols during placebo-controlled treatment of primary biliary cirrhosis with ursodeoxycholic acid or colchicine. <i>Hepatology</i> , 1995, 21, 1261-1268.	3.6	23

#	ARTICLE	IF	CITATIONS
91	Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. <i>Liver International</i> , 2008, 28, 787-797.	1.9	23
92	Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 821-830.	0.6	22
93	Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 242-249.	0.6	22
94	The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. <i>Liver International</i> , 2018, 38, 2329-2339.	1.9	22
95	Combined Effects of Alcohol and Metabolic Disorders in Patients With Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 995-997.e2.	2.4	22
96	PNPLA 3I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection. <i>BMC Medical Genetics</i> , 2012, 13, 82.	2.1	21
97	Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. <i>Journal of Hepatology</i> , 2022, 77, 302-311.	1.8	21
98	Cyclosporin Versus Infliximab in Severe Acute Ulcerative Colitis Refractory to Intravenous Steroids: A Randomized Trial. <i>Gastroenterology</i> , 2011, 140, S-112.	0.6	20
99	Clinical course and prognosis of pediatric-onset primary sclerosing cholangitis. <i>United European Gastroenterology Journal</i> , 2016, 4, 562-569.	1.6	20
100	Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF $\alpha$ -blocking agents. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 284-290.	0.6	20
101	Biliary Anomalies in Patients With HNF1B Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2075-2082.	1.8	20
102	Impact of Obesity on the Bioavailability of Peginterferon- $\alpha$ 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. <i>PLoS ONE</i> , 2012, 7, e37521.	1.1	19
103	Reducing Carcinogenic Acetaldehyde Exposure in the Achlorhydric Stomach With Cysteine. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 516-522.	1.4	18
104	A case report: Ulcerative colitis, treatment with an antibody against tumor necrosis factor (infliximab), and subsequent liver necrosis. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 724-727.	0.6	18
105	Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <i>United European Gastroenterology Journal</i> , 2021, 9, 1128-1135.	1.6	18
106	Dendritic Cells from Crohn's Disease Patients Show Aberrant STAT1 and STAT3 Signaling. <i>PLoS ONE</i> , 2013, 8, e70738.	1.1	18
107	Novel CARD15/NOD2 mutations in Finnish patients with Crohn's disease and their relation to phenotypic variation in vitro and in vivo. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 176-185.	0.9	17
108	Histologic surveillance after liver transplantation due to autoimmune hepatitis. <i>Clinical Transplantation</i> , 2017, 31, e12936.	0.8	17

#	ARTICLE	IF	CITATIONS
109	Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. <i>JAMA Oncology</i> , 2018, 4, 1576.	3.4	16
110	Genetic and lifestyle risk factors for advanced liver disease among men and women. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 291-298.	1.4	16
111	Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 839-847.	0.6	15
112	Environmental Risk Factors of Pediatric Onset Primary Sclerosing Cholangitis and Autoimmune Hepatitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016, 62, 437-442.	0.9	15
113	Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile. <i>Hepatology</i> , 2022, 75, 59-73.	3.6	15
114	Impact on follow-up strategies in patients with primary sclerosing cholangitis. <i>Liver International</i> , 2023, 43, 127-138.	1.9	15
115	Nizatidine and Gastric Emptying in Functional Dyspepsia. <i>Digestive Diseases and Sciences</i> , 2008, 53, 352-357.	1.1	14
116	Malignancies in inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 81-89.	0.6	14
117	Cohort profile: the Nordic Antireflux Surgery Cohort (NordASCo). <i>BMJ Open</i> , 2017, 7, e016505.	0.8	14
118	Fecal Calprotectin Test Performed at Home. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 926-931.	0.9	14
119	Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. <i>Gastroenterology</i> , 2022, 162, 431-438.e4.	0.6	14
120	Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. <i>Hepatology</i> , 2008, 48, 695-695.	3.6	13
121	Cancer incidence among alcoholic liver disease patients in Finland: A retrospective registry study during years 1996-2013. <i>International Journal of Cancer</i> , 2016, 138, 2616-2621.	2.3	13
122	Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamic trial and real-life experience. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 337-343.	0.6	13
123	Does oral L-galactosidase relieve irritable bowel symptoms?. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 16-21.	0.6	13
124	Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis. <i>Liver International</i> , 2017, 37, 735-742.	1.9	13
125	Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 849-854.	0.6	12
126	Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 707-711.	0.6	12



#	ARTICLE	IF	CITATIONS
127	Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries. <i>Annals of Surgery</i> , 2021, 274, e535-e540.	2.1	12
128	Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1180-1188.e4.	2.4	12
129	In Crohn's Disease, Anti-TNF- $\alpha$ Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells. <i>ISRN Gastroenterology</i> , 2012, 2012, 1-6.	1.5	11
130	Rapid faecal tests for detecting disease activity in colonic inflammatory bowel disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 825-832.	1.7	11
131	Suspicious brush cytology is an indication for liver transplantation evaluation in primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 6147-6154.	1.4	11
132	Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 321-327.	0.6	10
133	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00315.	1.3	10
134	Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2590-2600.	1.9	10
135	Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. <i>PLoS ONE</i> , 2016, 11, e0155142.	1.1	10
136	Outcome of inflammatory bowel disease patients treated with TNF- $\alpha$ inhibitors: two-year follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1476-1481.	0.6	9
137	<i>Clostridium difficile</i> infection in patients with inflammatory bowel disease: a case control study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 947-951.	0.6	9
138	Chronic cholestasis detection by a novel tool: automated analysis of cytokeratin 7-stained liver specimens. <i>Diagnostic Pathology</i> , 2021, 16, 41.	0.9	9
139	Effect of steatosis and inflammation on liver fibrosis in chronic hepatitis C. <i>Liver International</i> , 2009, 29, 153-158.	1.9	8
140	A randomized, controlled study of peginterferon lambda-1a/ribavirin±daclatasvir for hepatitis C virus genotype 2 or 3. <i>SpringerPlus</i> , 2016, 5, 1365.	1.2	8
141	Symptoms, endoscopic findings and histology predicting symptomatic benefit of <i>Helicobacter pylori</i> eradication. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 810-816.	0.6	7
142	<sup>31</sup> P magnetic resonance spectroscopy of the liver for evaluating inflammation and fibrosis in autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 886-892.	0.6	7
143	Diclofenac does not reduce the risk of acute pancreatitis in patients with primary sclerosing cholangitis after endoscopic retrograde cholangiography. <i>United European Gastroenterology Journal</i> , 2020, 8, 462-471.	1.6	7
144	Mortality, Reoperation, and Hospital Stay Within 90 Days of Primary and Secondary Antireflux Surgery in a Population-Based Multinational Study. <i>Gastroenterology</i> , 2021, 160, 2283-2290.	0.6	7

#	ARTICLE	IF	CITATIONS
145	Novel histological scoring for predicting disease outcome in primary sclerosing cholangitis. <i>Histopathology</i> , 2022, , .	1.6	7
146	Low prevalence of hepatitis C antibodies in chronic liver disease in finland. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 139-142.	1.5	6
147	A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e93601.	1.1	6
148	Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1251-1257.	0.8	6
149	Health-related quality of life before and after liver transplantation in patients with primary sclerosing cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 347-353.	0.6	6
150	Hospital Volume of Antireflux Surgery in Relation to Endoscopic and Surgical Re-interventions. <i>Annals of Surgery</i> , 2021, 274, e1138-e1143.	2.1	6
151	Gastroesophageal reflux patients' defective antioxidative capacity in the proximal esophageal mucosa before antireflux surgery and also after 4-year follow-up. <i>Annals of Medicine</i> , 2008, 40, 74-80.	1.5	5
152	Inflammatory bowel disease and anemia: intravenous iron treatment. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 430-434.	0.6	5
153	THU-251-Metabolic risk factors for advanced liver disease among alcohol risk users in the general population. <i>Journal of Hepatology</i> , 2019, 70, e273.	1.8	5
154	Antireflux surgery and risk of lung cancer by histological type in a multinational cohort study. <i>European Journal of Cancer</i> , 2020, 138, 80-88.	1.3	5
155	Laryngeal and Pharyngeal Squamous Cell Carcinoma After Antireflux Surgery in the 5 Nordic Countries. <i>Annals of Surgery</i> , 2022, 276, e79-e85.	2.1	5
156	Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. <i>Hepatology</i> , 2011, 53, 1067-1068.	3.6	4
157	Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 984-990.	0.6	3
158	LBP-01-In NAFLD, alcohol drinking habits and genetics predict progression to advanced liver disease: follow-up of population surveys. <i>Journal of Hepatology</i> , 2019, 70, e141.	1.8	3
159	Role of Autoimmunity in Patients Transplanted for Acute Liver Failure of Unknown Origin: A Clinical and Graft Biopsy Analysis. <i>Liver Transplantation</i> , 2020, 26, 764-773.	1.3	3
160	Low serum vitamin D level associated with incident advanced liver disease in the general population – a prospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 299-303.	0.6	3
161	Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?. <i>Clinical Infectious Diseases</i> , 2010, 50, e22-e25.	2.9	2
162	Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C. <i>PLoS ONE</i> , 2021, 16, e0251392.	1.1	2

#	ARTICLE	IF	CITATIONS
163	Psychiatric assessment of globus pharyngis patients. <i>Nordic Journal of Psychiatry</i> , 1992, 46, 303-306.	0.7	1
164	Noncholesterol Sterols as Surrogate Markers in Patients with Severe Alcoholic Hepatitis. <i>Lipids</i> , 2018, 53, 323-334.	0.7	1
165	REPLY:. <i>Hepatology</i> , 2020, 71, 1888-1889.	3.6	1
166	Presence of interferon- $\gamma$ 4, male gender, absent/mild steatosis and low viral load augment antibody levels to hepatitis C virus. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 849-854.	0.6	1
167	Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1020-1027.	0.4	1
168	Safety and efficacy of the JAK-inhibitor tofacitinib in patients with primary sclerosing cholangitis: a multicentre, retrospective study. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.2	1
169	Biliary hCG $\beta$ 2 Is a Potential Novel Marker for Prediction of Biliary Neoplasia in Primary Sclerosing Cholangitis Patients. <i>Livers</i> , 2021, 1, 322-329.	0.8	1
170	Incidence and Mortality of Peptic Ulcer Disease is Decreasing. <i>Gastroenterology</i> , 2011, 140, S-731.	0.6	0
171	This month in the <i>Scandinavian Journal of Gastroenterology</i> . <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 3-5.	0.6	0
172	Reply. <i>Hepatology</i> , 2014, 60, 2130-2131.	3.6	0
173	Insulin Resistance and Genetic Risk Predict Liver-Related Outcomes and Death in Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2019, 3, 1704-1705.	2.0	0
174	Immunoassay for trypsinogen-4. <i>Analytical Biochemistry</i> , 2022, , 114681.	1.1	0
175	Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?. <i>Scandinavian Journal of Gastroenterology</i> , 0, , 1-8.	0.6	0
176	Validation of the Chronic Liver Disease (CLivD) score. <i>Journal of Hepatology</i> , 2022, , .	1.8	0